EasyLife_Advisor

83 % rise expect acq me before first qtr of 2024,frm 27-11-23

Long
BSE_DLY:BACPHAR   BACIL PHARMA LTD.
Bacil Pharma Limited is an Indian pharmaceutical company specializing in the manufacture of bulk pharmaceutical drugs. Additionally, the company produces herbal extracts, drug intermediates, and other pharmaceutical products, including branded formulations, generic products, and OTC medications. Bacil Pharma's domestic operations are spread throughout India, and the company has a strong field force of over 500 members covering various states and districts.

**Key Information about Bacil Pharma Limited:**

* **Company Name:** Bacil Pharma Limited
* **Incorporation Date:** May 1987
* **Headquarters:** Palghar, Maharashtra, India
* **Primary Business:** Pharmaceutical Products
* **Products:** Bulk Pharmaceutical Drugs, Herbal Extracts, Drug Intermediates, Branded Formulations, Generic Products, OTC Medications
* **Market Capitalization:** ₹3.48 Crore (as of November 2023)

**Financial Performance of Bacil Pharma Limited:**

* **Revenue:** ₹4.64 Crore (FY2022-23)
* **Net Profit:** ₹-0.23 Crore (FY2022-23)

**Bacil Pharma Limited's Products:**

* **Bulk Pharmaceutical Drugs:** Bacil Pharma produces a wide range of bulk pharmaceutical drugs, including APIs, generics, and OTC products. The company focuses on manufacturing drugs for various therapeutic areas, such as cardiovascular, anti-infective, anti-diabetic, and anti-inflammatory drugs.

* **Herbal Extracts:** Bacil Pharma produces herbal extracts from various medicinal plants. The company uses a traditional extraction process to ensure the quality and purity of its herbal extracts. These extracts are used in the production of various pharmaceutical products, including traditional medicines and dietary supplements.

* **Drug Intermediates:** Bacil Pharma manufactures drug intermediates, which are the building blocks of various pharmaceutical products. The company produces a wide range of intermediates, including both APIs and non-APIs. Drug intermediates are an important part of the pharmaceutical manufacturing process, as they are used to create the active ingredients in various medications.

* **Branded Formulations:** Bacil Pharma produces branded formulations of various pharmaceutical products. These formulations are typically developed by the company and are sold under its own brand name. Branded formulations offer the advantage of brand recognition and can command premium pricing.

* **Generic Products:** Bacil Pharma also produces generic versions of various pharmaceutical products. Generic drugs are copies of brand-name drugs that have lost patent protection. Generic drugs are typically more affordable than brand-name drugs, and they can provide access to essential medicines for a wider population.

* **OTC Medications:** Bacil Pharma produces over-the-counter (OTC) medications, which are drugs that can be purchased without a prescription. OTC medications are typically for minor ailments, such as pain relief, fever reduction, and allergy relief.

**Investment Analysis of Bacil Pharma Limited:**

Bacil Pharma Limited is a small-cap company with a market capitalization of ₹3.48 Crore. The company has a strong track record of manufacturing quality pharmaceutical products and has a diverse product portfolio. However, the company's financial performance has been volatile in recent years, and it has experienced losses in the past.

**Risks of Investing in Bacil Pharma Limited:**

* **Small-cap company:** Bacil Pharma is a small-cap company with a low market capitalization, which makes it more susceptible to price fluctuations.
* **Volatile financial performance:** The company's financial performance has been volatile in recent years, which could make it a riskier investment than some other companies.
* **Competition:** The pharmaceutical industry is a highly competitive industry, and Bacil Pharma faces competition from both domestic and international companies.
* **Regulatory hurdles:** The pharmaceutical industry is subject to a number of regulatory hurdles, which can add to the complexity of the business.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.